|
業務類別
|
Biotechnology |
|
業務概覽
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatologyand rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. |
| 公司地址
| Dorfstrasse 29, Zug, CHE, 6300 |
| 電話號碼
| +41 415108022 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.moonlaketx.com |
| 員工數量
| 130 |
| Dr. Jorge Santos da Silva |
Interim Chairman of the Board and Chief Executive Officer |
美元 762.39K |
23/02/2026 |
| Dr. Kristian Reich |
Chief Scientific Officer |
美元 762.39K |
21/04/2026 |
| Mr. Matthias Bodenstedt |
Chief Financial Officer and Principal Accounting Officer |
美元 603.56K |
21/04/2026 |
|
|
| Ms. Catherine Moukheibir |
Independent Director |
21/04/2026 |
| Dr. Andrew Phillips, PhD |
Independent Director |
21/04/2026 |
| Mr. Spike Loy |
Lead Independent Director |
23/02/2026 |
| Dr. Jorge Santos da Silva |
Interim Chairman of the Board and Chief Executive Officer |
23/02/2026 |
| Dr. Ramnik Xavier |
Independent Director |
21/04/2026 |
|
|
|
|
